© FDNA Ltd. 2017 Yael HNRNPH2 mutation diagnosed at 24 monthsFDNA: Enabling Precision Medicine with Artificial Intelligence
- Genomic Insights through next-generation phenotyping

We use artificial intelligence to detect physiological patterns that reveal disease-causing genetic variations. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the game for precision medicine. Genetic code is at the core of most human diseases—whether in-born genetic errors that cause cancer, autism or other rare diseases, or genetic pathways that affect biological functions.

An Interpretation Challenge

Despite next-generation sequencing (NGS), becoming more available and affordable, the odds of finding a diagnosis through use of these technologies is limited to approximately 25% due to difficulty in identifying which genetic variants are clinically relevant.

FDNA’s database includes an unprecedented depth of phenotypic and genotypic information associated with over 10,000 diseases. All of our data is crowdsourced from real-world patient cases through our broad network of clinical, lab and research users. The de-identified data from thousands of cases each month is collected using our smart phenotyping applications (Face2Gene Suite), stored in a private and secure cloud-based clinical data warehouse, and integrated to LIMS, EMR and variant interpretation systems through a set of open APIs.

Our Technology© FDNA Ltd. 2018 - Technology

Our platform brings together a global network of clinical geneticists, the world’s top molecular labs, and an integrated network of researchers and academia, specializing in rare diseases. With users at more than 2,000 clinical sites globally, more than 65% of the clinical genetics market uses our platform as part of their routine workflow.

Our deep learning neural networks enable next-generation phenotyping (NGP) through analysis of photos, clinical features and genes using artificial intelligence algorithms.

Source: FDNA Ltd  אפ.די.אן.איי בע"מ

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Master of Health – Roche prepares itself for user innovation
Ursula B. Redeker, CEO of Roche Germany, the worldwide third largest region for Hoffmann-La Roche’s businesses about in-house gaps, partnerships, and managing disruptive transformations in healthcare

Steering Health Data For or By?
The User as Stakeholder, Expert, Citizen, Consumer, and Patient
Tomas D. Szucs, Chairman of Helsana Group, one of the largest Swiss health insurance companies, on making “big data” work and crossing traditional boundaries of managing information assets

Clarifying the concept of personalised medicine
Stem Cells - a discovery tool and a potential therapeutic modality. Jonathan Knowles, past Member of the Roche Executive Committee and Head of Group Research

Transition of Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Emerging Market Iran: How to shield your medical diagnostics assets
A snapshot accompanied by detailed experience of a veteran in the diagnostics industry doing business with Iran

European and U.S. Codes of Conduct for Development of Robotics and Artificial Intelligence

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only. Their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.